Layoffs are continuing to follow biopharma mergers, with workforce cuts tied to recent transactions projected to total more than 1,300 job losses across multiple companies. The report highlights that some cuts were disclosed shortly after acquisitions closed, reflecting early integration and overlap decisions. Among the largest items cited is CureVac’s acquisition by BioNTech, where 820 roles are expected to be eliminated. The coverage also points to Arcellx after Gilead closed the company’s $7.8 billion deal, and Amicus after BioMarin completed its $4.8 billion acquisition, both followed by WARN notices. For biotech operators, the implication is operational: integration-driven restructuring can quickly alter development headcount, priorities, and regional capabilities even when deal terms focus on pipeline and technology rather than staffing.